#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 7°C Friday 3 December 2021
Advertisement

New study shows how antidepressant could reduce Covid-19 hospitalisation risk

Fluvoxamine is traditionally used to treat mental health conditions such as depression and obsessive-compulsive disorders.

Image: Shutterstock/Zyabich

TREATING HIGH-RISK Covid-19 patients with the antidepressant fluvoxamine may reduce the risk of prolonged hospitalisation by up to a third, a large-scale study showed today.

Authors said the research could help boost low-cost protection against severe sickness or death in countries that have yet to receive adequate vaccine doses during a grossly uneven rollout.

Fluvoxamine is traditionally used to treat mental health conditions such as depression and obsessive-compulsive disorders and was selected for trial due to its anti-inflammatory properties.

Many problems stemming from Covid are caused by swelling as the immune system over-reacts to the infection.

Writing in the journal The Lancet Public Health, researchers from North and South America, described results in nearly 1,500 Covid-19 outpatients in Brazil.

Of the 741 people that received fluvoxamine, 79, just over 10%, had an extended stay in hospital.

Of the 756 who received a placebo, 119 (15.7%) were hospitalised.

Authors said that administering fluvoxamine resulted in a relative reduction in hospitalisations of 32%.

“Covid-19 still poses a risk to individuals in countries with low resources and limited access to vaccinations,” said Edward Mills of McMaster University, co-principal investigator on the trial.

“Identifying inexpensive, widely available, and effective therapies against Covid-19 is therefore of great importance, and re-purposing existing medications that are widely available and have well-understood safety profiles is of particular interest.”

#Open journalism No news is bad news Support The Journal

Your contributions will help us continue to deliver the stories that are important to you

Support us now

Although reducing deaths was not an intended area of focus, the study also found that 12 patients in the placebo group ended up dying, while just one from the fluvoxamine group succumbed to the virus.

The authors stressed that further evaluation is needed as fluvoxamine isn’t on the World Health Organization’s list of essential medicines and can be addictive.

“Given fluvoxamine’s safety, tolerability, ease of use, low cost, and widespread availability, these findings may have an important influence on national and international guidelines on clinical management of Covid-19,” said Gilmar Reis, study co-lead, based in Belo Horizonte, Brazil.

© AFP 2021

About the author:

AFP

Read next:

COMMENTS (42)

This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
write a comment

    Leave a commentcancel